Cargando…

Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies

BACKGROUND AND OBJECTIVE: Proprotein convertase subtilisin/kexin type 9 inhibition with monoclonal antibodies such as alirocumab significantly reduces low-density lipoprotein-cholesterol levels ± other lipid-lowering therapies. We aimed to develop and qualify a population pharmacokinetics (PopPK) mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Djebli, Nassim, Martinez, Jean-Marie, Lohan, Laura, Khier, Sonia, Brunet, Aurélie, Hurbin, Fabrice, Fabre, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591810/ https://www.ncbi.nlm.nih.gov/pubmed/28063030 http://dx.doi.org/10.1007/s40262-016-0505-1

Ejemplares similares

Combined Semi-mechanistic Target-Mediated Drug Disposition and Pharmacokinetic–Pharmacodynamic Models of Alirocumab, PCSK9, and Low-Density Lipoprotein Cholesterol in a Pooled Analysis of Randomized Phase I/II/III Studies
por: Nolain, Patrick, et al.
Publicado: (2022)

Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II
por: Nicolas, Xavier, et al.
Publicado: (2018)

Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I
por: Martinez, Jean-Marie, et al.
Publicado: (2018)

Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits
por: Djebli, Nassim, et al.
Publicado: (2016)

Population Pharmacokinetic Modeling and Determination of Individual Exposure to Avalglucosidase Alfa in Adolescent and Adult Patients With Late-Onset Pompe Disease: Analysis of Pooled Data From Phase I to III Clinical Trials
por: Tuffal, Gilles, et al.
Publicado: (2023)

Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors
por: Meneses-Lorente, Georgina, et al.
Publicado: (2021)

Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics
por: Bulitta, Jürgen B., et al.
Publicado: (2019)

Metabolism and Disposition of Tribendimidine and Its Metabolites in Healthy Chinese Volunteers
por: Yuan, Guiyan, et al.
Publicado: (2012)

A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects
por: Lunven, Catherine, et al.
Publicado: (2014)

Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature
por: Khier, Sonia, et al.
Publicado: (2018)

Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine
por: Chan Kwong, Anna H.-X. P., et al.
Publicado: (2020)

Pharmacokinetics of Oral Taurine in Healthy Volunteers
por: Ghandforoush-Sattari, Mohammadreza, et al.
Publicado: (2010)

Pharmacokinetics of chloroquine and primaquine in healthy volunteers
por: Daher, André, et al.
Publicado: (2022)

Pharmacokinetics of intranasal amiloride in healthy volunteers
por: Yellepeddi, Venkata K., et al.
Publicado: (2023)

Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers
por: Flanagan, Shawn, et al.
Publicado: (2018)

Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials
por: Leiter, L. A., et al.
Publicado: (2017)

A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics
por: Ming, Jeffrey E, et al.
Publicado: (2017)

Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials
por: Leiter, L. A., et al.
Publicado: (2018)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Population pharmacokinetics of olprinone in healthy male volunteers
por: Kunisawa, Takayuki, et al.
Publicado: (2014)

Pharmacokinetics of oral and intravenous melatonin in healthy volunteers
por: Andersen, Lars P. H., et al.
Publicado: (2016)

Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015)

Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers
por: Brazier, David, et al.
Publicado: (2017)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
por: Shin, Yesong, et al.
Publicado: (2022)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

Physiologically Based Pharmacokinetic Model To Predict Metoprolol Disposition in Healthy and Disease Populations
por: Zamir, Ammara, et al.
Publicado: (2023)

Cocaine: analysis, pharmacokinetics, and metabolic disposition.
por: Jatlow, P.
Publicado: (1988)

CYP2B6*6 Genotype Specific Differences in Artemether‐Lumefantrine Disposition in Healthy Volunteers
por: Abdullahi, Sa'ad T., et al.
Publicado: (2019)

Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers
por: Ancrenaz, Virginie, et al.
Publicado: (2013)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
por: Gupta, Neeraj, et al.
Publicado: (2020)

Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients
por: Hughes, Jim H., et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
por: Li, Haiyan, et al.
Publicado: (2020)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019)

Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers
por: Orrell, Catherine, et al.
Publicado: (2008)

Effect of Probenecid on Pharmacokinetics and Tolerability of Olmesartan in Healthy Chinese Volunteers()
por: Li, Kun-Yan, et al.
Publicado: (2014)

Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers
por: Zhang, Yi-fan, et al.
Publicado: (2016)

Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers
por: Birgersson, Sofia, et al.
Publicado: (2016)

Effects of Danshen Ethanol Extract on the Pharmacokinetics of Fexofenadine in Healthy Volunteers
por: Qiu, Furong, et al.
Publicado: (2014)

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ddsf9r0l4au3mb0fcomusqcffo